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Background: Although first-line therapy for patients affected by advanced mesothelioma is well established, there
is a lack of data regarding the impact of second-line treatment.
Methods: We retrospectively collected data of patients affected by advanced mesothelioma, already treated with
first-line therapy based on pemetrexed and platin, with a response (partial response or stable disease) lasting at
least 6 months, and re-treated with a pemetrexed-based therapy at progression. The primary objective was to
describe time to progression and overall survival after re-treatment.
Results: Overall across several Italian oncological Institutions we found 30 patients affected by advanced
mesothelioma, in progression after a 6-month lasting clinical benefit following a first-line treatment with cisplatin
and pemetrexed, and re-challenged with a pemetrexed-based therapy. In these patients we found a disease control
rate of 66%, with reduction of pain in 43% of patients. Overall time to progression and survival were promising for
a second-line setting of patients with advanced mesothelioma, being 5.1 and 13.6 months, respectively.
Conclusions: In our opinion, when a patient has a long-lasting benefit from previous treatment with pemetrexed
combined with a platin compound, the same treatment should be offered at progression.Background
The current standard of care in the management of
advanced malignant pleural mesothelioma is a platinum-
based chemotherapy [1]; a number of phase II trials have
suggested an activity for cisplatin and gemcitabine com-
bination [2,3], while the landmark trial is the one by
Vogelzang and Colleagues comparing cisplatin plus
pemetrexed to cisplatin alone, demonstrating a survival
benefit for the combination of 2.8 months versus cis-
platin alone [4]. A subsequent trial showed a 2.6-month
improvement in overall survival (OS) for the combin-
ation with cisplatin and raltitrexed versus cisplatin alone,
11.4 versus 8.8 months, respectively [5]. Although carbo-
platin has been shown to be less effective than cisplatin
in other malignancies like Non Small-Cell Lung Cancer
(NSCLC) [6], when cisplatin is contraindicated for* Correspondence: abearz@cro.it
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reproduction in any medium, provided the orcomorbidities, it may be replaced by carboplatin; more-
over several phase I and II trials where carboplatin was
combined with pemetrexed or gemcitabine in malignant
mesothelioma have given interesting results [7-9]. Due
to similar histologic features, treatment for peritoneal
mesothelioma has followed the same recommendations
[10,11].
No activity for second-line treatment has been clearly
reported in patients affected by malignant pleural meso-
thelioma; pemetrexed alone or combined with platin has
shown efficacy even in patients previously treated with
other drugs than pemetrexed [12,13], and some activity
has been demonstrated for vinorelbine [14].
In absence of a standard second-line treatment for ma-
lignant mesothelioma, we hypothesized efficacy from re-
treatment with pemetrexed alone or in combination with
platin, when time to progression (TTP), calculated from
the end of first-line chemotherapy and radiologic evi-
dence of progression, was greater or equal than
6 months, as suggested for other pathologies with few
therapeutic options [15]. We performed a retrospectivetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Characteristics of 30 patients with malignant
mesothelioma and retreated with pemetrexed-based
therapy as second-line therapy
N. (%)





—Palliative pleural decortications 11 (37)
—Extrapleural pneumonectomy 6 (20)
—Videothoracoscopy and pleurodesis 3 (10)
—Other 1 (3)
Never 9 (30)












Combination of first-line chemotherapy:
—Cisplatin and pemetrexed 21 (70)
—Carboplatin and pemetrexed 9 (30)
Response to first-line treatment:
—Stable Disease 15 (50)
Partial Response 15 (30)
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therapy in second line, to assess our hypothesis.
Methods
We retrospectively collected patients affected by meso-
thelioma from several Italian Institutions (IRCCS-
Aviano, IRCCS-S. Raffaele Milan, and General Hospitals
of Verona, Gorizia, Udine, Mirano, and Padova), after
obtaining approval from IRCCS – Aviano internal ethics
committee. In all these Institutions there was the policy
to re-treat all patients affected by advanced malignant
mesothelioma with the same drugs used in first line,
when certain features were observed. Patients had to be
treated with a pemetrexed-platin combination as first-
line chemotherapy, obtaining partial response (PR) or
stable disease (SD), with a further TTP greater or equal
than 6 months. We analyzed characteristics and out-
come only of those patients treated again with a
pemetrexed-based therapy after progression.
The regimens administered as re-treatment were
pemetrexed at a dose of 500 mg/m2 combined with a
platinum compound (cisplatin at a dose of 75 mg/m2 or
carboplatin at an area under the plasma concentration-
time curve –AUC - of 5 mg/ml/min) every three weeks
or pemetrexed single agent at a dose of 500 mg/m2 every
three weeks, using standard vitamin supplementation
and dexamethasone prophylaxis. All the patients had a
calculated creatinine clearance value (according to Cock-
croft and Gault formula [16]) greater than 45 mL/min,
and good hepatic and bone marrow activity. Before re-
treatment, all the patients were studied with a chest and
abdomen CT scan, repeated every two cycles. Responses
were evaluated through RECIST modified criteria for
mesothelioma [17]. Information on survival was
obtained through an active follow-up based on verifica-
tion of vital status of the patients, and survival analysis
was measured from the date of the first pemetrexed-
based re-treatment to death. If survival status was un-
known at the final follow-up, OS time was censored at
the last contact date. TTP was measured from the begin-
ning of second line of therapy to second relapse. OS and
TTP analyses were computed by the Kaplan-Meier
method [18], and log-rank test was used to test the dif-
ference between subgroups of treatment. In all cases,
statistical significant was claimed for ≤0.05.
Results
Between January 2005 and December 2009 we collected
30 patients from 7 Italian Institutions; their clinical char-
acteristics are reported in Table 1. The majority of all
patients were male (77%); with an ECOG Performance
Status (PS) of 1 in 15 patients (50%) and 0 in 15 (50%);
median age at diagnosis was 64.1 years. Sixteen patients
(53%) had a history of exposition to asbestos, while itwas unknown or unclear for all the others. Regarding
histology, 28 patients (93%) were affected by epithelioid
mesothelioma, and 2 (7%) by mixed. At diagnosis, stage
IV mesothelioma, according to IMIG classification, was
diagnosed in 12 out of 30 patients (40%), stage III in 8
(27%), stage II in 9 (30%), and one patient (3%) had an
extrapleural localization (tunical vaginalis). Nine
patients (30%) never underwent surgery; while all the
other had major surgery, in particular, 11 patients (37%)
had palliative pleural decortication; 6 (20%) extrapleural
pneumonectomy; 3 (10%) videothoracoscopy and pleur-
odesis, and 1 (3%) orchiectomy. Time from surgery to
the beginning of treatment with systemic chemotherapy
varied between 1 and 30 months; most of the patients
received chemotherapy just after recovery from surgery;
median time between surgery and the beginning of
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tumor assessable before the administration of first line
cisplatin and pemetrexed were included in the analysis.
All the patients received a combination of a platin
compound and pemetrexed as first line of treatment: 21
patients (70%) received cisplatin and pemetrexed, and 9
carboplatin combined with pemetrexed (30%). The me-
dian number of cycles of platin and pemetrexed combin-
ation administered as first-line therapy was 5.5 (range:
3–11). Response rate was as follows: 15 patients (50%)
showed a stability of the disease, and 15 (50%) a PR. All
of them showed progression, median TTP was
13 months (range: 6–57.5 months). At the beginning of
re-treatment with a pemetrexed-based rechallenge, PS
(ECOG) was 1 in 21 patients (70%) and 2 in 9 (30%)
(Table 2). For all the patients, pemetrexed-based re-
treatment was administered as second-line.
Median number of cycles at re-treatment was 4 (range:
3–9). The combination of choice was carboplatin plus
pemetrexed in 16 patients (53%), pemetrexed alone was
chosen in 9 patients (30%), and 5 patients (17%) received
cisplatin and pemetrexed again as they received for first-
line.
Modified RECIST criteria were available for 26 patients
out of 30; for three patients progression was due to a re-
lapse of pleural effusion and in one patient the retrieval
of the radiological images was not possible. Response
rate after re-treatment was as follows: 10 patients
showed progression of disease (33%), most of patientsTable 2 Efficacy of re-treatment with pemetrexed-based
chemotherapy in 30 patients affected by malignant
mesothelioma
N. (%)
N. of patients 30 (100)
Regimen of re-treatment:
—Pemetrexed 9 (30)
—Cisplatin + pemetrexed 5 (17)
—Carboplatin + pemetrexed 16 (53)
Response:
—Stable disease 15 (50)
—Partial response 5 (17)







—Absence of pain (before treatment and after) 7 (23)
—Pain reduction 13 (43)had stability of disease, 15 out of 30 patients (50%),
while 5 patients showed a partial response (17%); median
duration of stable disease in patients being retreated was
4.7 months.
TTP calculated from the beginning of re-treatment
with pemetrexed-based therapy and radiologic progres-
sion was 5.1 months (Figure 1). There was no significant
difference between TTP of the group of patients receiv-
ing pemetrexed combined with platin or pemetrexed
alone as re-challenge, 5.7 versus 4 months, respectively
(Figure 2).
Median OS, calculated from the beginning of re-
treatment to the last contact, was 13.6 months (Figure 3);
at the time of analysis at the end of June 2011, 20
patients had died and 10 were still alive.
We also collected information during re-treatment
about symptom control, based on VAS patient global as-
sessment [19,20]; all the Institutions were involved in a
monitoring program to ensure pain control, therefore
VAS administration was part of routine care. Pain
decreased in 13 out of 30 patients (43%), 7 patients
(23%) had no pain at all, while 10 patients (33%)
reported a worsening of their pain.
Discussion
Malignant mesothelioma is a very aggressive disease
with poor outcome even when radical surgery is pos-
sible; palliative chemotherapy is offered when patients
are not candidate for curative surgery; in randomized
clinical trials a platin-combination with pemetrexed or
raltitrexed have given better results [4,5]. Out of those
combinations, there are no recommended salvage ther-
apies, when patients experience a progression. For
other malignancies, when progression occurs at least
6 months after the end of previous treatment, a re-
challenge with the same drugs is offered because an
antiblastic activity is considered still possible. Based on
the lack of alternatives and in analogy with other ma-
lignancies, we proposed a re-treatment with the same
therapy used as first-line for patients affected by
advanced mesothelioma and progressed after obtaining
a benefit from first-line combination with platin and
pemetrexed. We collected data about 30 patients from
several Italian institutions, where the same policy was
applied. We found that re-treatment with pemetrexed
was feasible in all our patients; a more frequent com-
bination of pemetrexed with carboplatin instead of cis-
platin was chosen, likely due to an effort to avoid
neurologic or nephrologic toxicities from cisplatin.
Once again an interesting response was obtained, with
a clinical benefit observed in 20 out of 30 patients (dis-
ease control rate, DCR, 66%, PR and SD), both by
radiological assessment and reduction of pain. Overall
TTP and survival were promising for a second-line
Figure 1 Time to progression of 30 patients affected by mesothelioma and retreated with pemetrexed-based therapy at relapse after
first line chemotheraphy.
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and 13.6 months, respectively, considering other similar
reports from the literature: a French cohort, where sev-
eral different drugs were used in second-line for
patients affected by mesothelioma, showed 3.8 and
12.2 months, respectively for TTP and OS [21], while
in a mono-institutional Italian cohort salvage therapy
with gemcitabine-platin combination in second or fur-
ther line demonstrated 3 and 5.5 months, respectively
as TTP and OS [22]. We are aware that our group of
patients was selected for good prognostic factors, such
as PS, benefit after first-line treatment (SD or RP) and
a quite long TTP after the end of first-line treatment;
moreover no patient was affected by pure sarcomatoid
histotype, considered one of the worst prognostic fac-
tors [23,24]. We found a slightly better trend in TTP
for patients treated with a platin-pemetrexed combin-
ation even at re-treatment; however, the difference was
not statistically significant, and could just underline aFigure 2 Time to progression of 30 patients with mesothelioma by trbetter PS or younger age at the base of treatment
choice.
At the time of preparation of this manuscript it has
been just published a similar experience by Ceresoli and
Colleagues [25]. They collected data about a similar
casistic of patients, 31 patients, treated in a single Insti-
tute. Their population was a little different for the inclu-
sion criteria they set up for re-treatment with the same
drugs used as first-line, choosing to re-treat with a
pemetrexed-based therapy all the patients with a time to
progression greater or equal than 3 months after the end
of first line. In the Ceresoli’s paper, almost half of
patients were re-treated with pemetrexed-combination
as second-line, and half as further line of therapy, while
all our patients received pemetrexed alone or in combin-
ation with a platin compound as second-line therapy
only.
The difference in TTP after first-line as inclusion cri-
teria and pemetrexed-based re-treatment used beyondeatment (__Alimta vs.__Platinum+Alimta).
Figure 3 Overall survival of 30 patients affected by mesothelioma and retreated with pemetrexed-based theraph at relapse after first
line chemotheraphy.
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explain the shorter TTP and OS observed in Ceresoli’s
patients than in ours, 3.8 months and 5.1, respectively,
although any significant comparison can be drawn be-
tween the two groups of patients.Conclusions
Interestingly there are two papers, Ceresoli’s and ours,
with similar results. Our patients consistently support
the data from Ceresoli and Colleagues and strengthen
the results, also for the homogenously use of
pemetrexed-based re-treatment as second-line and the
multi-institutional collection of data. When patients had
a benefit from a platin-pemetrexed combination, in the
absence of other effective strategies, we strongly suggest
a re-treatment with the same drugs, because an im-
provement of the symptoms and a consistent gain in
TTP can be still obtained.
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